Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future
International Journal of Molecular Sciences · 2023
DOI: 10.3390/ijms242115674 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift International Journal of Molecular Sciences, 2023. Verfasst von Hanley N Abramson. Beteiligte Einrichtung: Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA. Hauptthemen laut MEDLINE: Multiple Myeloma, Antibodies, Bispecific. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 270 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
The landscape of therapeutic measures to treat multiple myeloma has undergone a seismic shift since the dawn of the current century. This has been driven largely by the introduction of new classes of small molecules, such as proteasome blockers (e.g., bortezomib) and immunomodulators (e.g., lenalidomide), as well as by immunotherapeutic agents starting with the anti-CD38 monoclonal antibody daratumumab in 2015. Recently, other immunotherapies have been added to the armamentarium of drugs available to fight this malignancy. These include the bispecifics teclistamab, talquetamab, and elranatamab, and the chimeric antigen receptor (CAR) T-cell products idecabtagene vicleucel (ide-cel) and ciltacabtagene autoleucel (cilta-cel). While the accumulated benefits of these newer agents have resulted in a more than doubling of the disease’s five-year survival rate to nearly 60% and improved quality of life, the disease remains incurable, as patients become refractory to the drugs and experience relapse. This review covers the current scope of antimyeloma immunotherapeutic agents, both those in clinical use and in development. Included in the discussion are additional monoclonal antibodies (mAbs), antibody–drug conjugates (ADCs), bi- and multitargeted mAbs, and CAR T-cells and emerging natural killer (NK) cells, including products intended for “off-the-shelf” (allogeneic) applications. Emphasis is placed on the benefits of each along with the challenges that need to be surmounted if MM is to be cured.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Pharmaceutical Sciences, Eugene Applebaum College of Pharmacy and Health Sciences, Wayne State University, Detroit, MI 48202, USA.
ORCID-Profile: Hanley N Abramson
Zitieren
APA
Abramson, H. N. (2023). Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future. International Journal of Molecular Sciences. https://doi.org/10.3390/ijms242115674
Vancouver
Abramson HN. Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future. International Journal of Molecular Sciences. 2023. doi:10.3390/ijms242115674
BibTeX
@article{Abramson2023,
author = {Abramson, Hanley N},
title = {Immunotherapy of Multiple Myeloma: Current Status as Prologue to the Future},
journal = {International Journal of Molecular Sciences},
year = {2023},
doi = {10.3390/ijms242115674}
}
EUVIMED